Weighing just 35.2g, the Xsens Avior is enclosed in a robust aluminum housing and has a rating of IP51 and an operating ...

Immunic (IMUX) announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, has been published in ...

Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at ...

Immunic Inc (NASDAQ: IMUX) completes the main analysis of Phase 1 CALVID-1 trial evaluating its lead asset, IMU-838. It is a selective oral DHODH inhibitor used in hospitalized patients with ...

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 Published Oct 15, 2023 6:30am EDT ...